Thyrocare on Thursday announced its financial results for the quarter and nine months ended December 31, 2024. According to the company’s statement, the diagnostics major reported revenue of Rs. 165.9 Cr in Q3FY25 with a growth of 23 percent YoY.
According to the company’s statement, Thyrocare’s consolidated revenue increased by 23% year-over-year (YoY) with Pathology and Radiology segments growing by 24% YoY and 13% YoY respectively.
Meanwhile, revenue from franchise surged by 24% YoY, and partnership revenue saw 23% YoY growth. The consolidated gross margin stood at 73%, and normalized EBITDA margin was 30%.
The company’s consolidated reported EBITDA grew by 32% YoY, while PAT increased by 30% YoY.
